Cost–utility analysis of adapted problem adaptation therapy for depression in mild-to-moderate dementia caused by Alzheimer's disease: PATHFINDER randomised controlled trial
Monica Panca(MRC Clinical Trials Unit at UCL), Rachael Hunter(MRC Clinical Trials Unit at UCL), Nick Freemantle(MRC Clinical Trials Unit at UCL), Sube Banerjee(University of Nottingham), Alan Thomas(Cleveland Clinic), Esme Moniz‐Cook(University of Hull), Rowan Harwood(University of Nottingham), Robert Howard(University College London), Charlotte Rawlinson(University College London), Gill Livingston(North East London NHS Foundation Trust), Philip Wilkinson(University of Oxford), Rebecca L. Gould(The London College), Elizabeth Cort(University College London), Chris Fox(University of California, Irvine), Anne Downey(MRC Clinical Trials Unit at UCL), Gregor Russell(Bradford District Care NHS Foundation Trust), Martin Wiegand(MRC Clinical Trials Unit at UCL)
Cited by 1
Related Papers
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
|The Lancet|2024|2.8k
Plastic waste associated with disease on coral reefs
|Science|2018|844
Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease
|New England Journal of Medicine|2012|774
Research criteria for the diagnosis of prodromal dementia with Lewy bodies
|Neurology|2020|772
Development of a TaqMan® PCR assay with internal amplification control for the detection of African swine fever virus
|Journal of Virological Methods|2003|541